Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2023 | Apr. 28, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2023 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | KYMR | |
Entity Registrant Name | KYMERA THERAPEUTICS, INC. | |
Entity Central Index Key | 0001815442 | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Common Stock, Shares Outstanding | 55,307,775 | |
Entity Shell Company | false | |
Entity File Number | 001-39460 | |
Entity Tax Identification Number | 81-2992166 | |
Entity Address, Address Line One | 200 Arsenal Yards Blvd | |
Entity Address, Address Line Two | Suite 230 | |
Entity Address, City or Town | Watertown | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 02472 | |
City Area Code | 857 | |
Local Phone Number | 285-5300 | |
Entity Interactive Data Current | Yes | |
Entity Incorporation, State or Country Code | DE | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
Security Exchange Name | NASDAQ |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 50,152 | $ 68,395 |
Marketable securities (Note 4) | 346,725 | 338,771 |
Contract assets | 3,320 | 2,537 |
Prepaid expenses and other current assets | 11,353 | 9,713 |
Total current assets | 411,550 | 419,416 |
Marketable securities, non-current (Note 4) | 119,017 | 152,328 |
Property and equipment, net (Note 6) | 17,432 | 13,334 |
Right-of-use assets, operating leases | 56,604 | 8,909 |
Other non-current assets | 3,155 | 3,017 |
Restricted cash | 6,147 | 6,130 |
Total assets | 613,905 | 603,134 |
Current liabilities: | ||
Accounts payable | 6,483 | 4,335 |
Accrued expenses (Note 8) | 18,502 | 27,502 |
Deferred revenue | 32,248 | 35,260 |
Operating lease liabilities | 2,554 | 2,535 |
Finance lease liabilities | 1,339 | 1,408 |
Other current liabilities | 807 | 303 |
Total current liabilities | 61,933 | 71,343 |
Non-current liabilities | ||
Deferred revenue, net of current portion | 24,866 | 28,000 |
Operating lease liabilities, net of current portion | 63,875 | 12,146 |
Finance lease liabilities, net of current portion | 989 | 1,246 |
Other non-current liabilities | 237 | 248 |
Total liabilities | 151,900 | 112,983 |
Stockholders’ equity: | ||
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2023 and December 31, 2022, 55,276,226 and 55,039,380 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 6 | 6 |
Additional paid-in capital | 889,755 | 878,884 |
Accumulated deficit | (424,718) | (383,790) |
Accumulated other comprehensive loss | (3,038) | (4,949) |
Total stockholders’ equity | 462,005 | 490,151 |
Total liabilities and stockholders’ equity | $ 613,905 | $ 603,134 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, authorized | 150,000,000 | 150,000,000 |
Common stock, issued | 55,276,226 | 55,039,380 |
Common Stock, outstanding | 55,276,226 | 55,039,380 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Collaboration Revenue—from related parties | $ 9,466 | $ 9,622 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | us-gaap:RevenueFromRelatedParties | us-gaap:RevenueFromRelatedParties |
Operating expenses: | ||
Research and development | $ 42,227 | $ 35,944 |
General and administrative | 12,565 | 10,611 |
Total operating expenses | 54,792 | 46,555 |
Loss from operations | (45,326) | (36,933) |
Other income (expense): | ||
Interest and other Income | 4,453 | 290 |
Interest and other expense | (55) | (41) |
Total other income: | 4,398 | 249 |
Net loss | (40,928) | (36,684) |
Other comprehensive loss: | ||
Unrealized (loss) gain on marketable securities | 1,911 | (2,556) |
Total comprehensive loss | (39,017) | (39,240) |
Net loss | $ (40,928) | $ (36,684) |
Net loss per share, basic and diluted | $ (0.70) | $ (0.71) |
Net loss per share, basic and diluted | $ (0.70) | $ (0.71) |
Weighted average common shares outstanding, basic and diluted | 58,187,038 | 51,651,125 |
Weighted average common shares outstanding, basic and diluted | 58,187,038 | 51,651,125 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid In Capital | Accumulated Deficit | Accumulated Other Comprehensive Gain (Loss) |
Beginning Balance at Dec. 31, 2021 | $ 459,638 | $ 5 | $ 689,275 | $ (228,982) | $ (660) |
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 | 51,536,181 | ||||
Exercise of stock options | 449 | 449 | |||
Exercise of stock options, Shares | 142,270 | ||||
Vesting restricted stock, Shares | 14,215 | ||||
Stock-based compensation expense | 7,873 | 7,873 | |||
Unrealized gain (loss) on marketable securities | (2,556) | (2,556) | |||
Net Loss | (36,684) | (36,684) | |||
Ending Balance at Mar. 31, 2022 | 428,720 | $ 5 | 697,597 | (265,666) | (3,216) |
Shares, Outstanding, Ending Balance at Mar. 31, 2022 | 51,692,666 | ||||
Beginning Balance at Dec. 31, 2022 | 490,151 | $ 6 | 878,884 | (383,790) | (4,949) |
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 | 55,039,380 | ||||
Exercise of stock options | 1,486 | 1,486 | |||
Exercise of stock options, Shares | 208,705 | ||||
Vesting restricted stock, Shares | 28,141 | ||||
Stock-based compensation expense | 9,385 | 9,385 | |||
Unrealized gain (loss) on marketable securities | 1,911 | 1,911 | |||
Net Loss | (40,928) | (40,928) | |||
Ending Balance at Mar. 31, 2023 | $ 462,005 | $ 6 | $ 889,755 | $ (424,718) | $ (3,038) |
Shares, Outstanding, Ending Balance at Mar. 31, 2023 | 55,276,226 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating activities | ||
Net loss | $ (40,928) | $ (36,684) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation expense | 9,385 | 7,873 |
Depreciation and amortization | 879 | 687 |
Premiums and discounts on available-for-sale marketable securities | (1,326) | 1,175 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other assets | (1,641) | (586) |
Contract asset—due from related parties | (783) | 1,128 |
Accounts payable | 2,217 | (1,437) |
Accrued expenses and other current liabilities | (10,037) | (2,278) |
Deferred revenue | (6,145) | (8,359) |
Operating lease right-of-use assets | 1,138 | 119 |
Operating lease liabilities | 2,915 | (227) |
Other assets and liabilities | 358 | 550 |
Net cash (used in) provided by operating activities | (43,968) | (40,295) |
Investing activities | ||
Purchase of property and equipment, net | (4,009) | (482) |
Purchases of investments | (61,835) | (80,118) |
Maturities of investments | 90,428 | 106,463 |
Net cash used in investing activities | 24,584 | 25,863 |
Financing activities | ||
Proceeds from stock option exercises | 1,486 | 449 |
Payments on finance leases | (327) | (264) |
Net cash provided by financing activities | 1,159 | 185 |
Net (decrease) increase in cash, cash equivalents and restricted cash | (18,225) | (14,247) |
Cash, cash equivalents and restricted cash at beginning of period | 74,524 | 54,092 |
Cash, cash equivalents and restricted cash at end of period | 56,299 | 39,845 |
Supplemental disclosure of cash flow activities | ||
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | 48,833 | 0 |
Cash paid for interest | 52 | 46 |
Supplemental disclosure of noncash investing and financing activities | ||
Property and equipment purchases included in accounts payable and accrued expenses | 1,100 | 126 |
Cash and cash equivalents | 50,152 | 33,733 |
Restricted cash | 6,147 | 6,112 |
Total cash, cash equivalents, and restricted cash | $ 56,299 | $ 39,845 |
Organization and Nature of Busi
Organization and Nature of Business | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Nature of Business | 1. Organization and Nature of Business Kymera Therapeutics, Inc., together with its subsidiary Kymera Securities Corporation, is referred to on a consolidated basis as the “Company”. The Company is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural cellular process, a method known as targeted protein degradation. The Company has devoted its efforts principally to research and development since formation. The Company has not yet completed product development, filed for or obtained regulatory approvals for any products, nor verified the market acceptance and demand for such products. As a result, the Company is subject to a number of risks common to emerging companies in the biotech industry. Principal among these risks are the uncertainties of the product discovery and development process, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors, protection of proprietary technology, compliance with government regulations and approval requirements, the Company’s ability to access capital and uncertainty of market acceptance of products. The Company has historical net losses and anticipates that it will continue to incur losses for the foreseeable future and had an accumulated deficit o f $ 424.7 million as of March 31, 2023. The Company has funded these losses principally through issuance of preferred stock, convertible notes, common stock, including its initial public offering and concurrent private placement completed in August 2020 (“IPO”), follow-on offering and concurrent private placement completed in July 2021 (“Follow-on Offering”), August 2022 Private Investment in Public Equity (“PIPE”) offering, and from cash proceeds received in connection with the Company’s collaboration agreements with Vertex Pharmaceuticals Incorporated (“Vertex”) and Genzyme Corporation (“Sanofi”) (see Note 5). The Company expects to continue to incur operating losses and negative cash flows until such time as it generates a level of revenue that is sufficient to support its cost structure. As of March 31, 2023, the Company had cash, cash equivalents and marketable securities of $ 515.9 million. The Company believes these cash, cash equivalents and marketable securities will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these condensed consolidated financial statements. The Company expects to finance the future research and development costs of its product portfolio with its existing cash, cash equivalents and marketable securities, or through strategic financing opportunities that could include, but are not limited to future offerings of its equity, collaboration agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials. Initial Public Offering On August 20, 2020, the Company’s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (“SEC”). In the IPO, which closed on August 25, 2020, the Company issued and sold 9,987,520 shares of common stock, including full exercise of the underwriters’ over-allotment option to purchase an additional 1,302,720 shares, at a public offering price of $ 20.00 per share and the aggregate gross proceeds before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company, were approximately $ 199.8 million. Concurrent with the IPO, the Company issued and sold 676,354 shares of common stock at $ 20.00 per share in a private placement to Vertex and the aggregate proceeds were $ 13.5 million. Follow-on Public Offering On July 6, 2021, the Company completed a follow-on offering of its common stock and issued and sold 5,468,250 shares of common stock, including full exercise of the underwriters’ over-allotment option to purchase an additional 713,250 shares, at a public offering price of $ 47.00 per share. The aggregate gross proceeds before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company were approximately $ 257.0 million. Concurrent with the follow-on offering, the Company issued and sold 49,928 shares of common stock at $ 47.00 per share in a private placement to Vertex and the aggregate proceeds were $ 2.3 million. Private Investment in Public Equity “PIPE” offering On August 18, 2022, the Company and certain accredited investors entered into a securities purchase agreement pursuant to which the Company agreed to sell and issue to such investors in a private placement (i) an aggregate of 2,769,228 shares of the Company’s common stock at a purchase price of $ 26.00 per share, and (ii) 3,000,000 pre-funded warrants to purchase common stock, at a purchase price of $ 25.9999 per Pre-Funded Warrant. The Pre-Funded Warrants will have an exercise price of $ 0.0001 per share of common stock. The offering closed on August 22, 2022, resulting in net proceeds of $ 149.8 million after offering expenses. As the pre-funded warrants are indexed to the Company’s common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the pre-funded warrants as additional paid-in capital on the Company’s consolidated balance sheets. The pre-funded warrants are exercisable at any time. The holders of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99 % of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99 % by providing at least 61 days’ prior notice to the Company. During the three months ended March 31, 2023, no pre-funded warrants were exercised. As of March 31, 2023, there were 3,000,000 pre-funded warrants outstanding. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies The accompanying condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note, and elsewhere in the accompanying condensed consolidated financial statements and notes. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation. Basis of Presentation The unaudited interim condensed consolidated financial statements of the Company included herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) as found in the Accounting Standards Codification (“ASC”), Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”) and the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the SEC on February 23, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments necessary, all of which were normal and recurring, for the fair statement of the Company’s financial position as of March 31, 2023, and the results of operations and cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of the results for the year ended December 31, 2023 or for any future period. Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2023 are consistent with those discussed in Note 2 to the consolidated financial statements in the 2022 Annual Report on Form 10-K. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 3. Fair Value Measurements The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2023 and December 31, 2022 (in thousands): Fair Value Measurements at Level 1 Level 2 Level 3 Total Assets: Cash equivalents Money market fund $ 47,829 $ — $ — $ 47,829 Marketable securities, current US treasuries 67,070 — — 67,070 US government agencies — 127,706 — 127,706 Corporate bonds — 151,949 — 151,949 Marketable securities, non-current US treasuries 5,840 — — 5,840 US government agencies — 72,180 — 72,180 Corporate bonds — 40,997 40,997 Restricted cash 6,147 — — 6,147 Total $ 126,886 $ 392,832 $ — $ 519,718 Fair Value Measurements at Level 1 Level 2 Level 3 Total Assets: Cash equivalents Money market fund $ 50,551 $ — $ — $ 50,551 Marketable securities, current US treasuries 74,045 — — 74,045 US government agencies - 120,467 — 120,467 Corporate bonds — 144,259 — 144,259 Marketable securities, non-current US treasuries 19,804 — — 19,804 US government agencies - 58,653 — 58,653 Corporate bonds — 73,871 — 73,871 Restricted cash 6,130 6,130 Total $ 150,530 $ 397,250 $ — $ 547,780 During the three months ended March 31, 2023 and the year ended December 31, 2022, there were no transfers in or out of Level 3. |
Marketable Securities
Marketable Securities | 3 Months Ended |
Mar. 31, 2023 | |
Marketable Securities [Abstract] | |
Marketable Securities | 4. Marketable Securities The following tables summarize the available-for-sale debt securities held at March 31, 2023 and December 31, 2022 (in thousands): Description Amortized Unrealized Unrealized Fair March 31, 2023 US treasury securities $ 73,589 $ 4 $ ( 683 ) $ 72,910 US government agencies 201,161 84 ( 1,359 ) 199,886 Corporate securities 194,027 89 ( 1,170 ) 192,946 Total $ 468,777 $ 177 $ ( 3,212 ) $ 465,742 Description Amortized Unrealized Unrealized Fair December 31, 2022 US treasury securities $ 94,958 $ 3 $ ( 1,111 ) $ 93,850 US government agencies 180,967 25 ( 1,873 ) 179,119 Corporate securities 220,119 25 ( 2,014 ) 218,130 Total $ 496,044 $ 53 $ ( 4,998 ) $ 491,099 As of March 31, 2023 , the Company held 130 securities that had been in an unrealized loss position for less than 12 months with an aggregate fair value of $ 291.7 million. As of December 31, 2022, the Company held 149 securities that had been in an unrealized loss position for less than 12 months with an aggregate fair value of $ 330.9 million. As of March 31, 2023, the Company held 38 securities that had been in an unrealized loss position for greater than 12 months with an aggregate fair value o f $ 102.5 million. As of December 31, 2022, the Company held 36 securities that had been in an unrealized loss position for greater than 12 months with an aggregate fair value of $ 115.0 million. As of March 31, 2023, the Company had 139 securities w ith a fair value of $ 346.7 million with a contractual maturity of less than 12 months and 61 securities with a fair value of $ 119.0 million with a contractual maturity of greater than 12 months. As of December 31, 2022 the Company had 118 securities with a fair value of $ 338.8 million with a contractual maturity of less than 12 months and 81 securities with a fair value of $ 152.3 million with a contractual maturity of greater than 12 months. There were no sales of marketable securities during the three months ending March 31, 2023 and 2022. The Company is required to determine whether a decline in the fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors. At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Factors considered in determining whether a loss resulted from a credit loss or other factors include the Company’s intent and ability to hold the investment until the recovery of its amortized cost basis, the extent to which the fair value is less than the amortized cost basis, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer’s industry, and any significant deterioration in economic conditions. Unrealized losses on available-for-sale securities presented in the previous table have not been recognized in the condensed consolidated statements of operations because the securities are high credit quality, investment grade securities that the Company does not intend to sell and will not be required to sell prior to their anticipated recovery, and the decline in fair value is attributable to factors other than credit losses. Based on its evaluation, the Company determined it does no t have any credit losses related to its available-for-sale securities as of March 31, 2023 and December 31, 2022. |
Collaborations
Collaborations | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaborations | 5. Collaborations Sanofi Collaboration Arrangement Agreement Terms On July 7, 2020, the Company entered into a collaboration agreement, or the Sanofi Agreement, with Sanofi, to co-develop drug candidates directed to two biological targets. Under the Sanofi Agreement, the Company granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration directed against IRAK4, or Collaboration Target 1, and one additional undisclosed target in an undisclosed field of use, or Collaboration Target 2. Such license is exercisable on a collaboration target-by-collaboration target basis only after specified milestones. For compounds directed against IRAK4, the field of use includes diagnosis, treatment, cure, mitigation or prevention of any diseases, disorders or conditions, excluding oncology and immuno-oncology. Pursuant to the Sanofi Agreement, the Company is responsible for discovery and preclinical research and conducting a Phase 1 clinical trial for at least one degrader directed against IRAK4 plus up to three backup degraders. With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate. In addition, pursuant to the Sanofi Agreement, Sanofi will grant to the Company an exclusive option, or Opt-In Right, exercisable on a collaboration target-by-collaboration target basis that will include the right to (i) to fund 50% of the United States development costs for collaboration products directed against such target in the applicable field of use and (ii) share equally in the net profits and net losses of commercializing collaboration products directed against such target in the applicable field of use in the United States. In addition, if the Company exercises the Opt-In Right, Sanofi will grant to the Company an exclusive option, applicable to each collaboration target, which upon exercise will allow the Company to conduct certain co-promotion activities in the field in the United States. The Sanofi Agreement, unless earlier terminated, will expire on a product-by-product basis on the date of expiration of all payment obligations under the Sanofi Agreement with respect to such product. The Company or Sanofi may terminate the agreement upon the other party’s material breach or insolvency or for certain patent challenges. In addition, Sanofi may terminate the Sanofi Agreement for convenience or for a material safety event upon advance prior written notice, and the Company may terminate the Sanofi Agreement with respect to any collaboration candidate if, following Sanofi’s assumption of responsibility for the development, commercialization or manufacturing of collaboration candidates with respect to a particular target, Sanofi ceases to exploit any collaboration candidates directed to such target for a specified period. In consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi paid to the Company an upfront payment of $ 150.0 million. The Company will also be reimbursed for certain research activities for a certain backup degrader under the IRAK4 program as well as contract manufacturing costs for the lead 474 program, unless certain criteria are not met for an initial IRAK4 degrader. In addition to the upfront payment and the reimbursements, the Company is eligible to receive certain development milestone payments of up to $ 1.48 billion in the aggregate, of which more than $ 1.0 billion relates to the IRAK4 program, upon the achievement of certain developmental or regulatory events. The Company will be eligible to receive certain commercial milestone payments up to $ 700.0 million in the aggregate, of which $ 400.0 million relates to the IRAK4 program, which are payable upon the achievement of certain net sales thresholds. The Company will be eligible to receive tiered royalties for each program on net sales ranging from the high-single digits to high teens, subject to low-single digits upward adjustments in certain circumstances. On November 15, 2022, we entered into an Amended and Restated Collaboration and License Agreement with Sanofi, or the Amended Sanofi Agreement, which amended the Original Sanofi Agreement to revise certain research terms and responsibilities set forth under the Original Sanofi Agreement. The Amended Sanofi Agreement also specifies details around the timing and number of Phase 2 trials required under the terms of the collaboration. The Amended Sanofi Agreement became effective on December 5, 2022. Additionally with respect to Sanofi, on December 2, 2022, Sanofi provided the Company with written notice of its intention to advance the collaboration target 1 candidate, KT-474, into Phase 2 clinical trials. The Company is entitled to receive milestone payments upon the dosing of the first Phase 2 patient(s) per indication up to a specified number of indications as further set forth in the Amended Sanofi Agreement. Accounting Treatment The Company analyzed the discovery and pre-clinical research activities as well as the exclusive license grants under the Sanofi Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606. The Company identified the following material promises under the arrangement: (1) research services for Collaboration Target 1, (2) research license for Collaboration Target 1, (3) exclusive license for Collaboration Target 1, (4) research services for Collaboration Target 2, (5) research license for Collaboration Target 2, (6) exclusive license for Collaboration Target 2, (7) option to extend the research term, and (8) optional research services during the development period. The Company determined that Collaboration Targets 1 and 2 are distinct from each other. The research associated with degraders directed to each target is at different stages and the licensed field, should development activities be successful, are different from each other. As such, all promises associated with each target are considered distinct from promises associated with the other target. The research and development services for each collaboration target were determined not to be distinct from the research license and the exclusive license and have been combined into a single performance obligation for each collaboration target. That is, two performance obligations were identified, the combined research services, research license and exclusive license for Collaboration Target 1 and the combined research services, research license and exclusive license for Collaboration Target 2. The exclusive license for each target is not distinct from the pre-clinical and clinical research and development services under the Sanofi Agreement, primarily due to the highly specialized nature of the research and novel technology involved with developing protein degraders – the pre-clinical activities and studies and first phase 1 clinical trial could not be conducted by another party in the manner required. The option to extend the research term and optional research services during the development period were evaluated as material rights. The fees associated with each option are at or above the standalone selling price. As such, the underlying options are not performance obligations and fees associated with each option are excluded from the transaction price until the underlying option is exercised. The Company determined the total transaction price to be $ 150.0 million, which consists solely of the upfront payment. All milestone payments and option payments are constrained as the achievement of such milestones are contingent upon the success of the underlying research and development activities and are generally outside the control of the Company. The reimbursement of costs for the IRAK4 backup degrader is also treated as constrained variable consideration as the criteria for reimbursement may not always be met, under which circumstances the Company would be responsible for the costs related to the backup degrader. Upon becoming unconstrained, the reimbursement consideration will be added to the transaction price and allocated to Collaboration Target 1. The Company allocated the upfront payment to each performance obligation based on the relative standalone selling price, as follows: • Collaboration Target 1: $ 120.0 million • Collaboration Target 2: $ 30.0 million The Company determined the allocation of the $ 150.0 million transaction price between Collaboration Target 1 and Collaboration Target 2 based on the value of the research and development for the programs from projected research and development costs for each collaboration target plus a developer’s profit and the total potential milestones for each collaboration target. The Company recognizes revenue associated with each performance obligation as the research and development services are provided using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying each performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company’s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. Reimbursement consideration added to the transaction price will be recognized as revenue on the same pattern as Collaboration Target 1, with a cumulative catch-up upon becoming unconstrained. The performance obligations have not been fully satisfied as of March 31, 2023. In the three months ended March 31, 2023, the Company recognized $ 7.7 million in revenue under the Sanofi Agreement, of which $ 7.1 million was associated with Collaboration Target 1 and $ 0.6 million was associated with Collaboration Target 2. In the three months ended March 31, 2022, the Company recognized $ 6.6 million in revenue under the Sanofi Agreement, of which $ 4.2 million was associated with Collaboration Target 1 and $ 2.4 million was associated with Collaboration Target 2. Of the $ 7.7 million of revenue recognized in the three months ended March 31, 2023, $ 5.5 million was recognized from amounts that were recorded in deferred revenue as of December 31, 2022. The aggregate amount of the transaction price allocated to the Company’s unsatisfied performance obligations and recorded in deferred revenue at March 31, 2023 and December 31, 2022 is $ 50.5 million and $ 54.9 million, respectively. During the three months ended March 31, 2023, the Company received $ 2.5 million in cost reimbursement payments. No milestone or royalty payments have been received under the Sanofi Agreement. As of March 31, 2023, the Company recorded a contract asset for unbilled accounts receivable of $ 3.3 million related to reimbursable research and development costs under the Sanofi Agreement for activities performed during the first quarter of 2023. As of March 31, 2023, the Company did no t have any amounts recorded in accounts receivable under the Sanofi Agreement. The Company will recognize the deferred revenue related to the remaining performance obligations based on a cost input method, as described, over the remaining research term, which is approximately 2.8 years as of March 31, 2023. Any consideration related to performance-based milestones will be recognized when the risk of probable reversal is resolved, at which point the Company shall adjust the transaction price determined for the agreement accordingly and recognize revenue on a cumulative-catch up basis, reallocating the revised arrangement consideration to the performance obligations. Any consideration related to sales milestone payments and royalties will be recognized when the related milestone events or sales occur and therefore are recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. As part of its evaluation of constraining the milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones are contingent upon the results of the underlying research and development activities and are thus outside of the control of the Company. Vertex Agreement On May 9, 2019 (the “Effective Date”), the Company entered into a collaboration agreement (the “Vertex Agreement”) with Vertex to advance small molecule protein degraders against up to six targets. Under the Vertex Agreement, Vertex has the exclusive option to license the rights to the product candidates developed for the designated targets at which point Vertex will control development and commercialization. Pursuant to the Vertex Agreement, the Company is only responsible for discovery and preclinical research on the targets, and Vertex is responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of the collaboration is four ( 4 ) years, extendable for an additional one ( 1 ) year period upon mutual agreement by the parties and payment by Vertex of certain per-target fees. Vertex provided the Company with a non-refundable upfront payment of $ 50.0 million and purchased 3,059,695 shares of the Company’s Series B-1 Convertible Preferred Stock (the “Series B-1 Preferred Stock”) at $ 6.54 a share, pursuant to a separate, but simultaneously executed Share Purchase Agreement. The shares were purchased at a premium of $ 5.9 million, which was included in the transaction price and will be recognized as revenue over the period of performance. As a result of this purchase, Vertex is considered a related party. The Company is eligible to receive up to $ 170.0 million in payments per target, including development, regulatory and commercial milestones as well as option exercise payments. In addition, Vertex is obligated to pay the Company tiered royalties on future net sales on any products that may result from the Vertex Agreement. None of the payments under the Vertex Agreement are refundable. The Company may also perform follow-on research for an optioned target upon Vertex’s request and at Vertex’s expense. The term of the Vertex Agreement began on the Effective Date and expires upon the expiration of all payment obligations from Vertex to Company under the Vertex Agreement or, if Vertex does not exercise any of its options, the lapse of all Vertex’s option rights under the Vertex Agreement. Vertex also has the ability to terminate for convenience with prior written notice to the Company, and either party may terminate for an uncured material breach. Accounting Treatment The Company analyzed the joint research activities required under the Vertex Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research license; (2) the research and development services to be performed on up to six targets; and (3) the option to license each of the targets for development, manufacturing, and commercialization efforts. The research and development services were determined not to be distinct from the research and development license and have been combined into a single performance obligation. The Company determined that the option to license the targets in the future was not priced at a discount, and that the option exercise fee for each target is at or above the standalone selling price for research at this stage of development; as such, the options and the underlying licenses are excluded from the performance obligation and the option exercise fees are excluded from the transaction price until the underlying option is exercised. As part of its evaluation of constraining the research and development milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones is contingent upon the results of the underlying research and development activities and is thus outside of the control of the Company. At the commencement of the arrangement, two units of accounting were identified: the issuance of 3,059,695 shares of the Series B-1 Preferred Stock and the research activities the Company will perform over the Research Term. The Company determined the total transaction price to be $ 55.9 million, which consists of $ 5.9 million attributed to the premium from the shares of Series B-1 Preferred Stock sold to Vertex and the $ 50.0 million upfront payment. To determine the fair value of the Series B-1 Preferred Stock issued to Vertex, the Company performed a valuation of the shares of the Company’s common and preferred stock, which took into consideration recent financings, and the Company’s recent development and future exit strategies, as well as a discount for lack of marketability. The Company recognizes revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred as related to the research and development activities on each program and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company’s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. The performance obligation has not been fully satisfied as of March 31, 2023. During the three months ended March 31, 2023 and 2022, the Company recognized $ 1.8 million and $ 3.0 million, respectively, under the Vertex Agreement. All $ 1.8 million of revenue recognized in the three months ended March 31, 2023 was recognized from amounts that were recorded in deferred revenue as of December 31, 2022. The aggregate amount of the transaction price allocated to the Company’s unsatisfied performance obligation and recorded in deferred revenue at March 31, 2023 and December 31, 2022 is $ 6.6 million and $ 8.4 million, respectively. The Company will recognize the deferred revenue related to the remaining performance obligation based on a cost input method, as described, over the remaining research term. Kymera expects that the collaboration will expire upon completion of the initial research term. Accordingly, the Company expects to fully satisfy its performance obligation and recognize any remaining deferred revenue at that time. Any consideration related to sales milestone payments (including royalties) will be recognized when the related milestone events or sales occur and therefore is recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. The following table presents the changes in accounts receivable, contract ass ets and contract liabilities for the three months ended March 31, 2023 (in thousands): Balance at Additions Deductions Balance at Accounts receivable and contract assets: Billed receivables - Sanofi $ — $ 2,537 $ ( 2,537 ) $ — Unbilled receivables - Sanofi 2,537 3,320 ( 2,537 ) 3,320 Total accounts receivable and contract assets $ 2,537 $ 5,857 $ ( 5,074 ) $ 3,320 Contract liabilities: Deferred revenue - Vertex $ 8,399 $ — $ ( 1,825 ) $ 6,574 Deferred revenue - Sanofi 54,861 3,320 ( 7,641 ) 50,540 Total contract liabilities $ 63,260 $ 3,320 $ ( 9,466 ) $ 57,114 |
Property and Equipment
Property and Equipment | 3 Months Ended |
Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | 6. Property and Equipment Property and equipment consists of the following as of March 31, 2023 and December 31, 2022 (in thousands): March 31, December 31, Lab and office equipment under finance right-of-use asset $ 5,475 $ 5,475 Lab equipment 4,435 4,383 Computer equipment 440 357 Furniture & fixtures 1,064 1,064 Leasehold improvements 7,802 7,802 Assets not yet in service 6,007 1,146 Total property and equipment 25,223 20,227 Less accumulated depreciation ( 7,791 ) ( 6,893 ) Property and equipment, net $ 17,432 $ 13,334 Depreciation expense for the three months ended March 31, 2023 and 2022 was $ 0.9 million and $ 0.7 million, respectively. Included in property and equipment is lab and office equipment right-of-use assets under finance leases with a cost basis of $ 5.5 million and $ 5.5 million and accumulated amortization expense of $ 3.0 million and $ 2.7 million as of March 31, 2023 and December 31, 2022, respectively. Amortization expense related to right-of-use assets during the three months ended March 31, 2023 and 2022 was $ 0.4 million and $ 0.3 million, respectively. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
Leases | 7. Leases In October 2019, the Company entered into a noncancelable facility lease agreement (the “the 2019 Lease”) for 34,522 square feet of research and development and office space in Watertown, Massachusetts. The term of the 2019 Lease is 120 months and expires on March 31, 2030 . The 2019 Lease has an option to be extended for an additional five years . The lease is not reasonably certain to be extended and as such the additional term is not included in the measurement of the lease. The 2019 Lease includes a rent escalation clause, and rent expense is being recorded on a straight-line basis. In accordance with the lease agreement, the Company is required to maintain a security deposit and provided a letter of credit to the landlord for $ 1.6 million, which is recorded in restricted cash as of March 31, 2023 and December 31, 2022. In December 2021, the Company entered into a noncancelable lease (the “2021 Lease”) for 100,624 square feet of office and laboratory space in Watertown, Massachusetts, which the Company expects to begin occupying in November 2023 . The 2021 Lease is subject to base rent of $ 0.8 million per month beginning two months after the commencement date, plus the Company’s ratable share of taxes, maintenance and other operating expenses. Base rent is subject to a 3 % annual increase over the lease term of approximately 134 months following the commencement date. The Company also has two consecutive options to extend the term of the lease for five years each at then-market rates. The 2021 Lease also includes a tenant improvement allowance of approximately $ 20.1 million. In connection with the signing of the 2021 Lease, the Company issued a letter of credit for $ 4.5 million which is classified as restricted cash as of March 31, 2023 and December 31, 2022. The Company also paid first month’s rent of $ 0.8 million u pon execution of the 2021 Lease in December 2021 which is classified as other non-current assets as of March 31, 2023 and December 31, 2022. The 2021 Lease required the landlord to build-out the base building prior to the construction of the Company’s premises. The Company concluded the accounting commencement date occurred when the landlord completed the build-out of the base building and control passed to the Company, which occurred in early January 2023. The Company assessed the classification of the 2021 Lease at the accounting commencement date and concluded the lease should be accounted for as an operating lease. The Company recorded an operating lease liability of $ 48.9 million, measured as the present value of the remaining lease payments discounted using the incremental borrowing rate as of the accounting commencement date. The Company recorded an operating lease right-of-use asset of $ 48.9 million, measured as the present value of the remaining lease payments, net of the tenant incentives. The Company concluded the improvements paid for by the landlord in connection with the tenant improvement allowance represent lessee assets and therefore recorded $ 2.2 million of leasehold improvements in property and equipment. The Company recorded an additional $ 1.4 million of leasehold improvements in excess of the tenant improvement allowance, all of which were not placed in service as of March 31, 2023. The Company’s finance lease obligations consist of certain property and equipment financed through finance leases. The components of the lease costs for the three months ended March 31, 2023 and 2022, were as follows (in thousands): Three Months Ended 2023 2022 Operating lease costs $ 2,521 $ 524 Finance lease costs: Amortization of right-to-use assets, finance leases 369 279 Interest expense for finance lease liabilities 52 46 Variable lease costs 220 329 Total lease costs $ 3,162 $ 1,178 Supplemental cash flow information relating to the Company’s leases for the three months ended March 31, 2023 and 2022, were as follows (in thousands): Three Months Ended 2023 2022 Cash paid for amounts included in the measurement Operating cash flows used in operating leases $ 651 $ 631 Operating cash flows used in finance leases $ 327 $ 264 Financing cash flows used in finance leases $ 52 $ 46 Weighted average remaining lease terms and discount rates as of March 31, 2023 and 2022 were as follows: Three Months Ended 2023 2022 Remaining lease term: Operating lease 10.75 years 8.09 years Finance lease 2.33 years 2.10 years Discount Rate: Operating lease 8.87 % 10.50 % Finance lease 8.52 % 8.75 % The undiscounted future lease payments for operating and finance leases as of March 31, 2023, were as follows (in thousands): Fiscal Year Operating Finance 2023 (excluding the first quarter) ( 15,639 ) 1,084 2024 11,482 839 2025 12,142 402 2026 12,506 133 2027 12,881 100 Thereafter 85,143 — Total minimum lease payments 118,515 2,558 Less amounts representing interest or imputed interest ( 52,086 ) ( 230 ) Present value of lease liabilities 66,429 2,328 The undiscounted future lease payments in 2023 includes approximately $ 17.6 million of future reimbursements related to landlord funded tenant improvements in connection with the 2021 Lease. |
Accrued Expenses
Accrued Expenses | 3 Months Ended |
Mar. 31, 2023 | |
Accrued Liabilities, Current [Abstract] | |
Accrued Expenses | 8. Accrued Expenses Accrued expenses consist of the following as of March 31, 2023 and December 31, 2022 (in thousands): March 31, December 31, Research and development expenses $ 11,097 $ 16,975 Payroll and payroll-related 3,592 8,149 Professional fees 2,287 1,971 Other 1,526 407 Accrued expenses $ 18,502 $ 27,502 |
Other Commitments and Contingen
Other Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Other Commitments and Contingencies | 9. Other Commitments and Contingencies Legal Proceedings In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any legal proceedings. Indemnification Arrangements As permitted under Delaware law, the Company has agreements whereby it indemnifies its investors, employees, officers, and directors (collectively, the “Indemnified Parties”) for certain events or occurrences while the Indemnified Parties are, or were serving, at its request in such capacity. The term of the indemnification period is for the Indemnified Parties’ lifetime. The Company believes the estimated fair value of these indemnification agreements is minimal. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company’s products. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company is not aware of any claims under indemnification arrangements, and it has no t accrued any liabilities related to such obligations as of March 31, 2023 or December 31, 2022. |
Equity-Based Compensation
Equity-Based Compensation | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Equity-Based Compensation | 10. Equity-Based Compensation 2018 Stock Option and Grant Plan In November 2018, the Company adopted, and its stockholders approved, the 2018 Stock Option and Grant Plan (the “2018 Plan”), which provides for the granting of stock options and other equity-based awards at the discretion of the Board of Directors or any subcommittee of the Board of Directors to the Company’s employees, officers, directors, and independent contractors. No further grants will be made under the 2018 Plan. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder. To the extent outstanding options granted under the 2018 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2018 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Option and Incentive Plan. 2020 Stock Option and Incentive Plan In August 2020, the Company and its stockholders approved the 2020 Stock Option and Incentive Plan (the “2020 Plan”), which became effective on August 20, 2020. The 2020 Plan replaced the 2018 Plan as the Company’s Board of Directors has determined not to make additional awards under the 2018 Plan following the closing of the Company’s IPO. The 2020 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved 4,457,370 shares of its common stock for the issuance of awards under the 2020 Plan, which includes the shares of common stock remaining available for issuance under its 2018 Plan as of the business day immediately prior to the effective date of the registration statement. The 2020 Plan provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter, by 4 % of the Company’s outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s compensation committee. These limits are subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. As of March 31, 2023, there were an aggregate of 4,003,824 s hares remaining available for future grants. 2020 Employee Stock Purchase Plan In August 2020, the Company and its stockholders approved the 2020 Employee Stock Purchase Plan (the “2020 ESPP”), which became effective August 20, 2020. The 2020 ESPP initially reserves and authorizes the issuance of up to a total of 445,653 shares of common stock to participating employees. The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the lesser of (i) 438,898 shares of common stock, (ii) 1 % of the Company’s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP . The number of shares reserved under the 2020 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. As of March 31, 2023, there were an aggregate 1,647,150 s hares remaining available for future grants. Stock Options A summary of stock option activity under the 2020 Plan during the three months ended March 31, 2023 is as follows (in thousands except share and per share data): Number of Weighted Weighted Aggregate Outstanding at December 31, 2022 6,757,289 $ 27.60 8.01 $ 55,934 Granted 1,930,540 31.25 Exercised ( 208,705 ) 7.12 Forfeited ( 187,393 ) 39.41 Outstanding at March 31, 2023 8,291,731 $ 28.70 8.27 $ 67,120 Exercisable at March 31, 2023 3,711,610 $ 24.28 7.42 $ 48,572 The intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 was $ 5.5 million and $ 6.2 million, respectively. The weighted-average fair value of options granted during the three months ended March 31, 2023 and 2022 was $ 18.67 and $ 22.96 per share, respectively. As of March 31, 2023, the total unrecognized stock-based compensation expense for unvested stock options was $ 82.5 million, with a weighted average recognition period of 2.4 years. The following table outlines our equity-based compensation expense for stock options for the three months ended March 31, 2023 and 2022: Three Months Ended 2023 2022 Research and development $ 4,184 $ 3,689 General and administrative 4,349 3,912 Total equity-based compensation $ 8,533 $ 7,601 The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant date fair value of stock options granted to employees and non-employees for the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended 2023 2022 Expected term (in years) 5.82 5.81 Volatility 62 % 62 % Risk-free interest rate 4.14 % 1.59 % Dividend yield 0.00 % 0.00 % Restricted Common Stock The Company has granted shares of restricted common stock with service-based and performance-based vesting conditions. A summary of restricted stock activity during the three months ended March 31, 2023 is as follows: Number of Grant Date Unvested at December 31, 2022 281,843 $ 23.64 Granted 216,289 30.84 Vested ( 28,141 ) 38.53 Forfeited ( 17,270 ) 25.84 Unvested at March 31, 2023 452,721 $ 26.07 During the three months ended March 31, 2023 and 2022, the Company granted 216,289 and 97,974 shares of restricted common stock, respectively. As of March 31, 2023, the total unrecognized stock-based compensation expense for unvested restricted stock was $ 10.9 million with a weighted average recognition period of 2.8 years. During the three months ended March 31, 2023 the Company recognized approximately $ 0.6 million of expense for restricted stock of which $ 0.4 million and $ 0.2 million was recorded in research and development and general and administrative expense, respectively. During the three months ended March 31, 2022 the Company recognized approximately $ 0.1 million for restricted stock of which an immaterial amount were included in research and development and general and administrative expense, respectively Equity-Based Compensation Expense Total equity-based compensation expense recorded as research and development and general and administrative expenses for employees, directors, and non-employees during the three months ended March 31, 2023 and 2022 is as follows (in thousands): Three Months Ended 2023 2022 Research and development $ 4,729 $ 3,906 General and administrative 4,656 3,967 Total equity-based compensation $ 9,385 $ 7,873 |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 11. Related-Party Transactions Other than the collaborations discussed in Note 5, the Company had no related party transactions for the periods presented in the accompanying condensed consolidated financial statements, which have not otherwise been discussed in these notes to the condensed consolidated financial statements. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 12. Income Taxes Income taxes for the three months ended March 31, 2023 and 2022 have been calculated based on an estimated annual effective tax rate and certain discrete items. For the three months ended March 31, 2023 and 2022, no income tax was recorded. The Company has never been examined by the Internal Revenue Service or any other jurisdiction for any tax years and, as such, all years within the applicable statutes of limitations are potentially subject to audit. |
Net Loss per Share
Net Loss per Share | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Net Loss per Share | 13. Net Loss per Share Net Loss per Share Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding for the period, including the pre-funded warrants given their nominal exercise price (in thousands, except for share and per share data): Three Months Ended 2023 2022 Numerator: Net loss $ ( 40,928 ) $ ( 36,684 ) Denominator: Weighted average common shares outstanding, basic and 58,187,038 51,651,125 Net loss per share, basic and diluted $ ( 0.70 ) $ ( 0.71 ) The Company’s potentially dilutive securities, which include restricted stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at March 31, 2023 and 2022 because including them would have had an anti-dilutive effect: Three Months Ended 2023 2022 Unvested restricted stock 452,721 121,504 Options to purchase common stock 8,291,731 7,119,524 Total 8,744,452 7,241,028 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation. |
Basis of Presentation | Basis of Presentation The unaudited interim condensed consolidated financial statements of the Company included herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) as found in the Accounting Standards Codification (“ASC”), Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”) and the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the SEC on February 23, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments necessary, all of which were normal and recurring, for the fair statement of the Company’s financial position as of March 31, 2023, and the results of operations and cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of the results for the year ended December 31, 2023 or for any future period. |
Significant Accounting Policies | Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2023 are consistent with those discussed in Note 2 to the consolidated financial statements in the 2022 Annual Report on Form 10-K. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets Measured at Fair Value on Recurring Basis | The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2023 and December 31, 2022 (in thousands): Fair Value Measurements at Level 1 Level 2 Level 3 Total Assets: Cash equivalents Money market fund $ 47,829 $ — $ — $ 47,829 Marketable securities, current US treasuries 67,070 — — 67,070 US government agencies — 127,706 — 127,706 Corporate bonds — 151,949 — 151,949 Marketable securities, non-current US treasuries 5,840 — — 5,840 US government agencies — 72,180 — 72,180 Corporate bonds — 40,997 40,997 Restricted cash 6,147 — — 6,147 Total $ 126,886 $ 392,832 $ — $ 519,718 Fair Value Measurements at Level 1 Level 2 Level 3 Total Assets: Cash equivalents Money market fund $ 50,551 $ — $ — $ 50,551 Marketable securities, current US treasuries 74,045 — — 74,045 US government agencies - 120,467 — 120,467 Corporate bonds — 144,259 — 144,259 Marketable securities, non-current US treasuries 19,804 — — 19,804 US government agencies - 58,653 — 58,653 Corporate bonds — 73,871 — 73,871 Restricted cash 6,130 6,130 Total $ 150,530 $ 397,250 $ — $ 547,780 |
Marketable Securities (Tables)
Marketable Securities (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Marketable Securities [Abstract] | |
Summary of Available-for-Sale Debt Securities | The following tables summarize the available-for-sale debt securities held at March 31, 2023 and December 31, 2022 (in thousands): Description Amortized Unrealized Unrealized Fair March 31, 2023 US treasury securities $ 73,589 $ 4 $ ( 683 ) $ 72,910 US government agencies 201,161 84 ( 1,359 ) 199,886 Corporate securities 194,027 89 ( 1,170 ) 192,946 Total $ 468,777 $ 177 $ ( 3,212 ) $ 465,742 Description Amortized Unrealized Unrealized Fair December 31, 2022 US treasury securities $ 94,958 $ 3 $ ( 1,111 ) $ 93,850 US government agencies 180,967 25 ( 1,873 ) 179,119 Corporate securities 220,119 25 ( 2,014 ) 218,130 Total $ 496,044 $ 53 $ ( 4,998 ) $ 491,099 |
Collaborations (Tables)
Collaborations (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Change in Accounts Receivable, Contract Asset and Liabilities | The following table presents the changes in accounts receivable, contract ass ets and contract liabilities for the three months ended March 31, 2023 (in thousands): Balance at Additions Deductions Balance at Accounts receivable and contract assets: Billed receivables - Sanofi $ — $ 2,537 $ ( 2,537 ) $ — Unbilled receivables - Sanofi 2,537 3,320 ( 2,537 ) 3,320 Total accounts receivable and contract assets $ 2,537 $ 5,857 $ ( 5,074 ) $ 3,320 Contract liabilities: Deferred revenue - Vertex $ 8,399 $ — $ ( 1,825 ) $ 6,574 Deferred revenue - Sanofi 54,861 3,320 ( 7,641 ) 50,540 Total contract liabilities $ 63,260 $ 3,320 $ ( 9,466 ) $ 57,114 |
Property and Equipment (Tables)
Property and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Summary of Property and Equipment | Property and equipment consists of the following as of March 31, 2023 and December 31, 2022 (in thousands): March 31, December 31, Lab and office equipment under finance right-of-use asset $ 5,475 $ 5,475 Lab equipment 4,435 4,383 Computer equipment 440 357 Furniture & fixtures 1,064 1,064 Leasehold improvements 7,802 7,802 Assets not yet in service 6,007 1,146 Total property and equipment 25,223 20,227 Less accumulated depreciation ( 7,791 ) ( 6,893 ) Property and equipment, net $ 17,432 $ 13,334 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
Components of Lease Costs | The components of the lease costs for the three months ended March 31, 2023 and 2022, were as follows (in thousands): Three Months Ended 2023 2022 Operating lease costs $ 2,521 $ 524 Finance lease costs: Amortization of right-to-use assets, finance leases 369 279 Interest expense for finance lease liabilities 52 46 Variable lease costs 220 329 Total lease costs $ 3,162 $ 1,178 |
Supplemental Cash Flow Information Relating to Leases | Supplemental cash flow information relating to the Company’s leases for the three months ended March 31, 2023 and 2022, were as follows (in thousands): Three Months Ended 2023 2022 Cash paid for amounts included in the measurement Operating cash flows used in operating leases $ 651 $ 631 Operating cash flows used in finance leases $ 327 $ 264 Financing cash flows used in finance leases $ 52 $ 46 |
Summary of Weighted Average Remaining Lease Terms and Discount Rates | Weighted average remaining lease terms and discount rates as of March 31, 2023 and 2022 were as follows: Three Months Ended 2023 2022 Remaining lease term: Operating lease 10.75 years 8.09 years Finance lease 2.33 years 2.10 years Discount Rate: Operating lease 8.87 % 10.50 % Finance lease 8.52 % 8.75 % |
Summary of Undiscounted Future Lease Payments for Operating and Finance Leases | The undiscounted future lease payments for operating and finance leases as of March 31, 2023, were as follows (in thousands): Fiscal Year Operating Finance 2023 (excluding the first quarter) ( 15,639 ) 1,084 2024 11,482 839 2025 12,142 402 2026 12,506 133 2027 12,881 100 Thereafter 85,143 — Total minimum lease payments 118,515 2,558 Less amounts representing interest or imputed interest ( 52,086 ) ( 230 ) Present value of lease liabilities 66,429 2,328 The undiscounted future lease payments in 2023 includes approximately $ 17.6 million of future reimbursements related to landlord funded tenant improvements in connection with the 2021 Lease. |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Accrued Liabilities, Current [Abstract] | |
Schedule of Accrued Liabilities | Accrued expenses consist of the following as of March 31, 2023 and December 31, 2022 (in thousands): March 31, December 31, Research and development expenses $ 11,097 $ 16,975 Payroll and payroll-related 3,592 8,149 Professional fees 2,287 1,971 Other 1,526 407 Accrued expenses $ 18,502 $ 27,502 |
Equity-Based Compensation (Tabl
Equity-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Summary of Stock Option Activity | A summary of stock option activity under the 2020 Plan during the three months ended March 31, 2023 is as follows (in thousands except share and per share data): Number of Weighted Weighted Aggregate Outstanding at December 31, 2022 6,757,289 $ 27.60 8.01 $ 55,934 Granted 1,930,540 31.25 Exercised ( 208,705 ) 7.12 Forfeited ( 187,393 ) 39.41 Outstanding at March 31, 2023 8,291,731 $ 28.70 8.27 $ 67,120 Exercisable at March 31, 2023 3,711,610 $ 24.28 7.42 $ 48,572 |
Summary of Equity-Based Compensation Expense | Total equity-based compensation expense recorded as research and development and general and administrative expenses for employees, directors, and non-employees during the three months ended March 31, 2023 and 2022 is as follows (in thousands): Three Months Ended 2023 2022 Research and development $ 4,729 $ 3,906 General and administrative 4,656 3,967 Total equity-based compensation $ 9,385 $ 7,873 |
Summary of Weighted-Average Assumptions | The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant date fair value of stock options granted to employees and non-employees for the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended 2023 2022 Expected term (in years) 5.82 5.81 Volatility 62 % 62 % Risk-free interest rate 4.14 % 1.59 % Dividend yield 0.00 % 0.00 % |
Stock Options | |
Summary of Equity-Based Compensation Expense | The following table outlines our equity-based compensation expense for stock options for the three months ended March 31, 2023 and 2022: Three Months Ended 2023 2022 Research and development $ 4,184 $ 3,689 General and administrative 4,349 3,912 Total equity-based compensation $ 8,533 $ 7,601 |
Summary of Restricted Stock Activity | The Company has granted shares of restricted common stock with service-based and performance-based vesting conditions. A summary of restricted stock activity during the three months ended March 31, 2023 is as follows: Number of Grant Date Unvested at December 31, 2022 281,843 $ 23.64 Granted 216,289 30.84 Vested ( 28,141 ) 38.53 Forfeited ( 17,270 ) 25.84 Unvested at March 31, 2023 452,721 $ 26.07 |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Summary of Basic and Diluted Loss Per Share | Three Months Ended 2023 2022 Numerator: Net loss $ ( 40,928 ) $ ( 36,684 ) Denominator: Weighted average common shares outstanding, basic and 58,187,038 51,651,125 Net loss per share, basic and diluted $ ( 0.70 ) $ ( 0.71 ) |
Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect | The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at March 31, 2023 and 2022 because including them would have had an anti-dilutive effect: Three Months Ended 2023 2022 Unvested restricted stock 452,721 121,504 Options to purchase common stock 8,291,731 7,119,524 Total 8,744,452 7,241,028 |
Organization and Nature of Bu_2
Organization and Nature of Business - Additional Information (Details) - USD ($) | 3 Months Ended | ||||
Aug. 18, 2022 | Jul. 06, 2021 | Aug. 25, 2020 | Mar. 31, 2023 | Dec. 31, 2022 | |
Organization and Nature of Business [Line Items] | |||||
Accumulated deficit | $ 424,718,000 | $ 383,790,000 | |||
Cash, cash equivalents and marketable securities | $ 515,900 | ||||
Initial Public Offering | |||||
Organization and Nature of Business [Line Items] | |||||
Stock Issued During Period, Shares, New Issues | 9,987,520 | ||||
Common stock per share | $ 20 | ||||
Gross proceeds from issuance initial public offering | $ 199,800,000 | ||||
Private Placement | Vertex Pharmaceuticals Incorporated | |||||
Organization and Nature of Business [Line Items] | |||||
Stock Issued During Period, Shares, New Issues | 49,928 | 676,354 | |||
Common stock per share | $ 47 | $ 20 | |||
Aggregate proceeds from issuance of private placement | $ 2,300,000 | $ 13,500,000 | |||
Underwriters | |||||
Organization and Nature of Business [Line Items] | |||||
Stock Issued During Period, Shares, New Issues | 713,250 | 1,302,720 | |||
Follow-on Offering | |||||
Organization and Nature of Business [Line Items] | |||||
Net proceeds from sale of common stock in public offering | $ 257,000,000 | ||||
Stock Issued During Period, Shares, New Issues | 5,468,250 | ||||
Common stock per share | $ 47 | ||||
Private Investment in Public Equity "PIPE" | |||||
Organization and Nature of Business [Line Items] | |||||
Stock Issued During Period, Shares, New Issues | 2,769,228 | ||||
Common stock per share | $ 26 | ||||
Pre-funded warrants to purchase | $ 3,000,000,000 | ||||
Pre-funded warrant purchase price | $ 25.9999 | ||||
Pre-funded warrants per share | $ 0.0001 | ||||
Offering expenses | $ 149,800,000 | ||||
Pre-funded warrants outstanding | 3,000,000 | ||||
Pre-funded warrants, exercised | $ 0 | ||||
Increase or decrease pre-funded warrants, maximum | 19.99% | ||||
Minimum pre-funded warrants, exercise | 4.99% | ||||
Prior notice period, minimum | 61 days |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Additional Information (Details) | Jun. 30, 2022 |
Significant Accounting Policies [Line Items] | |
Change in accounting principle, accounting standards update, adopted | true |
Change in accounting principle, accounting standards update, immaterial effect | true |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Restricted cash | $ 6,147 | $ 6,130 |
Total | 519,718 | 547,780 |
Money Market Fund | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents | 47,829 | 50,551 |
US government agencies | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 72,180 | 58,653 |
Marketable securities, non-current | 127,706 | 120,467 |
Corporate Bonds | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 40,997 | 73,871 |
Marketable securities, non-current | 151,949 | 144,259 |
US Treasuries | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 5,840 | 19,804 |
Marketable securities, non-current | 67,070 | 74,045 |
Level 1 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Restricted cash | 6,147 | 6,130 |
Total | 126,886 | 150,530 |
Level 1 | Money Market Fund | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents | 47,829 | 50,551 |
Level 1 | US government agencies | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 0 | 0 |
Marketable securities, non-current | 0 | 0 |
Level 1 | Corporate Bonds | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 0 | |
Marketable securities, non-current | 0 | |
Level 1 | US Treasuries | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 5,840 | 19,804 |
Marketable securities, non-current | 67,070 | 74,045 |
Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Restricted cash | 0 | |
Total | 392,832 | 397,250 |
Level 2 | Money Market Fund | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents | 0 | 0 |
Level 2 | US government agencies | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 72,180 | 58,653 |
Marketable securities, non-current | 127,706 | 120,467 |
Level 2 | Corporate Bonds | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 40,997 | 73,871 |
Marketable securities, non-current | 151,949 | 144,259 |
Level 2 | US Treasuries | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 0 | |
Marketable securities, non-current | 0 | 0 |
Level 3 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Restricted cash | 0 | |
Total | 0 | |
Level 3 | Money Market Fund | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents | 0 | 0 |
Level 3 | US government agencies | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 0 | |
Marketable securities, non-current | 0 | |
Level 3 | Corporate Bonds | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | ||
Marketable securities, non-current | 0 | |
Level 3 | US Treasuries | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Marketable securities, current | 0 | |
Marketable securities, non-current | $ 0 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Fair Value Disclosures [Abstract] | ||
Fair value assets, level 1 to level 3 transfers, amount | $ 0 | $ 0 |
Fair value assets, level 3 to level 1 transfers, amount | 0 | 0 |
Fair value assets, level 3 to level 2 transfers, amount | 0 | 0 |
Fair value assets, level 2 to level 3 transfers, amount | $ 0 | $ 0 |
Marketable Securities - Summary
Marketable Securities - Summary of Available-for-Sale Debt Securities (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Marketable Securities [Line Items] | ||
Amortized Cost | $ 468,777 | $ 496,044 |
Unrealized Gains | 177 | 53 |
Unrealized Losses | (3,212) | (4,998) |
Fair Value | 465,742 | 491,099 |
U.S. Treasury Securities | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 73,589 | 94,958 |
Unrealized Gains | 4 | 3 |
Unrealized Losses | (683) | (1,111) |
Fair Value | 72,910 | 93,850 |
US Government Agencies | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 201,161 | 180,967 |
Unrealized Gains | 84 | 25 |
Unrealized Losses | (1,359) | (1,873) |
Fair Value | 199,886 | 179,119 |
Corporate Securities | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 194,027 | 220,119 |
Unrealized Gains | 89 | 25 |
Unrealized Losses | (1,170) | (2,014) |
Fair Value | $ 192,946 | $ 218,130 |
Marketable Securities - Additio
Marketable Securities - Additional Information (Details) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 USD ($) Security | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) Security | |
Marketable Securities [Abstract] | |||
Number of available-for-sale debt securities, continuous unrealized loss position for less than 12 months | Security | 130 | 149 | |
Aggregate fair value of available-for-sale debt securities, continuous unrealized loss position for less than 12 months | $ 291,700,000 | $ 330,900,000 | |
Number of available-for-sale debt securities, contractual maturity of less than 12 months | Security | 139 | 118 | |
Fair value of available-for-sale debt securities, contractual maturity of less than 12 months | $ 346,700,000 | $ 338,800 | |
Number of available-for-sale debt securities, contractual maturity of greater than 12 months | Security | 61 | 81 | |
Fair value of available-for-sale debt securities, contractual maturity of greater than 12 months | $ 119,017,000 | $ 152,328,000 | |
Aggregate fair value of available-for-sale debt securities, continuous unrealized loss position for greater than 12 months | 102,500,000 | 115,000,000 | |
Sales of marketable securities | 0 | $ 0 | |
Available-for-sale securities, credit losses | $ 0 | $ 0 | |
Number of securities decline in market value for in an unrealized loss position | Security | 38 | 36 |
Collaborations - Additional Inf
Collaborations - Additional Information (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Jul. 07, 2020 | May 09, 2019 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Cost reimbursement payment received | $ 2,500,000 | ||||
Unbilled accounts receivable | 3,300,000 | ||||
Research and development | $ 42,227,000 | $ 35,944,000 | |||
Remaining research term of collaboration | 2 years 9 months 18 days | ||||
Revenue recognized | $ 9,466,000 | 9,622,000 | |||
Sanofi Agreement | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Upfront payment | $ 150,000,000 | ||||
Collaboration agreement transaction price | 150,000,000 | ||||
Revenue recognized recorded in deferred revenue | 7,700,000 | ||||
Unsatisfied performance obligation | 50,500,000 | $ 54,900,000 | |||
Milestone receivable | 0 | ||||
Research and development | 0 | ||||
Revenue recognized | 7,700,000 | 6,600,000 | 5,500 | ||
Sanofi Agreement | Collaboration Target 1 | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Collaboration agreement transaction price | 120,000,000 | ||||
Revenue recognized recorded in deferred revenue | 7,100,000 | 4,200,000 | |||
Sanofi Agreement | Collaboration Target 2 | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Collaboration agreement transaction price | 30,000,000 | ||||
Revenue recognized recorded in deferred revenue | 600,000 | ||||
Revenue recognized | 2,400,000 | ||||
Sanofi Agreement | Maximum | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Development milestone payments | 1,480,000,000 | ||||
Commercial Milestone Payments | 700,000,000 | ||||
Sanofi Agreement | Minimum | IRAK4 Program | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Development milestone payments | 1,000,000,000 | ||||
Commercial Milestone Payments | $ 400,000,000 | ||||
Vertex Agreement | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Revenue recognized recorded in deferred revenue | 1,800,000 | ||||
Unsatisfied performance obligation | 6,600,000 | $ 8,400,000 | |||
Initial research term of collaboration | 4 years | ||||
Extended research term of collaboration | 1 year | ||||
Revenue recognized | $ 1,800,000 | $ 3,000,000 | |||
Vertex Agreement | Series B-1 Preferred Stock | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Collaboration agreement transaction price | $ 55,900,000 | ||||
Non refundable upfront payment received | $ 50,000,000 | ||||
Issuance of shares, Shares | 3,059,695 | ||||
Stock issued price per share | $ 6.54 | ||||
Preferred stock premium | $ 5,900,000 | ||||
Vertex Agreement | Maximum | |||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
Eligible to receive payments including development, regulatory and commercial milestones | $ 170,000,000 |
Collaborations - Change in Acco
Collaborations - Change in Accounts Receivable, Contract Asset and Liabilities (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
Accounts receivable and contract assets, Beginning balance | $ 2,537 |
Accounts receivable and contract assets, Additions | 5,857 |
Accounts receivable and contract assets, Deductions | (5,074) |
Accounts receivable and contract assets, Ending balance | 3,320 |
Contract Liabilities, Beginning balance | 63,260 |
Contract Liabilities, Additions | 3,320 |
Contract Liabilities, Deductions | (9,466) |
Contract Liabilities, Ending balance | 57,114 |
Billed Receivables - Sanofi | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
Accounts receivable and contract assets, Beginning balance | 0 |
Accounts receivable and contract assets, Additions | 2,537 |
Accounts receivable and contract assets, Deductions | 2,537 |
Accounts receivable and contract assets, Ending balance | 0 |
Unbilled Receivables - Sanofi | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
Accounts receivable and contract assets, Beginning balance | 2,537 |
Accounts receivable and contract assets, Additions | 3,320 |
Accounts receivable and contract assets, Deductions | 2,537 |
Accounts receivable and contract assets, Ending balance | 3,320 |
Deferred Revenue - Vertex | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
Contract Liabilities, Beginning balance | 8,399 |
Contract Liabilities, Additions | 0 |
Contract Liabilities, Deductions | (1,825) |
Contract Liabilities, Ending balance | 6,574 |
Deferred Revenue - Sanofi | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |
Contract Liabilities, Beginning balance | 54,861 |
Contract Liabilities, Additions | 3,320 |
Contract Liabilities, Deductions | (7,641) |
Contract Liabilities, Ending balance | $ 50,540 |
Property and Equipment - Summar
Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 25,223 | $ 20,227 |
Less accumulated depreciation | (7,791) | (6,893) |
Property and equipment, net | 17,432 | 13,334 |
Lab and Office Equipment Under Finance Right of Use Asset | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 5,475 | 5,475 |
Lab Equipment | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 4,435 | 4,383 |
Computer Equipment | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 440 | 357 |
Furniture & Fixtures | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 1,064 | 1,064 |
Leasehold Improvements | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 7,802 | 7,802 |
Assets Not Yet in Service | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 6,007 | $ 1,146 |
Property and Equipment - Additi
Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Property Plant And Equipment [Line Items] | |||
Depreciation expense | $ 900 | $ 700 | |
Property and equipment right of use assets under finance leases with cost basis | 25,223 | $ 20,227 | |
Amortization of right-to-use assets, finance leases | 369 | $ 279 | |
Lab and Office Equipment Under Finance Right of Use Asset | |||
Property Plant And Equipment [Line Items] | |||
Property and equipment right of use assets under finance leases with cost basis | 5,475 | 5,475 | |
Accumulated amortization | $ 3,000 | $ 2,700 |
Leases - Additional Information
Leases - Additional Information (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Dec. 20, 2021 USD ($) ft² | Oct. 31, 2019 ft² | Mar. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Lessee Lease Description [Line Items] | ||||
Operating Lease, Liability, Noncurrent | $ 63,875 | $ 12,146 | ||
Undiscounted Future Lease Payments | 17,600 | |||
Land, Buildings and Improvements [Member] | ||||
Lessee Lease Description [Line Items] | ||||
Operating Lease, Liability, Noncurrent | 48,900 | |||
Operating Lease, Payments | 48,900 | |||
landlord [Member] | ||||
Lessee Lease Description [Line Items] | ||||
Property And Equipment Improvements | 2,200 | |||
Tenant Improvement Allowance | 1,400 | |||
Watertown, Massachusetts | ||||
Lessee Lease Description [Line Items] | ||||
Lease term | 134 months | |||
Watertown, Massachusetts | Noncancelable Facility Lease Agreement | ||||
Lessee Lease Description [Line Items] | ||||
Area of office space | ft² | 100,624 | 34,522 | ||
Lease term | 120 months | |||
Lease expiration date | Mar. 31, 2030 | |||
Lease additional term | 5 years | 5 years | ||
Tenant incentive allowance receivable | $ 20,100 | |||
Base Rent | $ 800 | |||
Annual increase percentage of rent | 3% | |||
Rent paid | 800 | 800 | ||
Watertown, Massachusetts | Noncancelable Facility Lease Agreement | Restricted Cash | Letter of Credit | 2019 Lease | ||||
Lessee Lease Description [Line Items] | ||||
Security deposit | 1,600 | 1,600 | ||
Watertown, Massachusetts | Noncancelable Facility Lease Agreement | Restricted Cash | Letter of Credit | 2021 Lease | ||||
Lessee Lease Description [Line Items] | ||||
Security deposit | $ 4,500 | $ 4,500 | ||
Watertown, Massachusetts | Facility Sublease Agreement | ||||
Lessee Lease Description [Line Items] | ||||
Lease commencement date | Nov. 30, 2023 |
Leases - Components of Lease Co
Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Leases [Abstract] | ||
Operating lease costs | $ 2,521 | $ 524 |
Amortization of right-to-use assets, finance leases | 369 | 279 |
Interest expense for finance lease liabilities | 52 | 46 |
Variable lease costs | 220 | 329 |
Total lease costs | $ 3,162 | $ 1,178 |
Leases - Supplemental Cash Flow
Leases - Supplemental Cash Flow Information Relating to Leases (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Leases [Abstract] | ||
Operating cash flows used in operating leases | $ 651 | $ 631 |
Operating cash flows used in finance leases | 327 | 264 |
Financing cash flows used in finance leases | $ 52 | $ 46 |
Leases - Summary of Weighted Av
Leases - Summary of Weighted Average Remaining Lease Terms and Discount Rates (Details) | Mar. 31, 2023 | Mar. 31, 2022 |
Leases [Abstract] | ||
Operating lease, remaining lease term | 10 years 9 months | 8 years 1 month 2 days |
Finance lease, remaining lease term | 2 years 3 months 29 days | 2 years 1 month 6 days |
Operating lease, discount rate | 8.87% | 10.50% |
Finance lease, discount rate | 8.52% | 8.75% |
Leases - Summary of Undiscounte
Leases - Summary of Undiscounted Future Lease Payments for Operating and Finance Leases (Details) $ in Thousands | Mar. 31, 2023 USD ($) |
Operating Leases | |
2023 (excluding the first quarter) | $ (15,639) |
2024 | 11,482 |
2025 | 12,142 |
2026 | 12,506 |
2027 | 12,881 |
Thereafter | 85,143 |
Total minimum lease payments | 118,515 |
Less amounts representing interest or imputed interest | (52,086) |
Present value of lease liabilities | 66,429 |
Finance Leases | |
2023 (excluding the first quarter) | 1,084 |
2024 | 839 |
2025 | 402 |
2026 | 133 |
2027 | 100 |
Thereafter | 0 |
Total minimum lease payments | 2,558 |
Less amounts representing interest or imputed interest | (230) |
Present value of lease liabilities | $ 2,328 |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Accrued Liabilities, Current [Abstract] | ||
Research and development expenses | $ 11,097 | $ 16,975 |
Payroll and payroll-related | 3,592 | 8,149 |
Professional fees | 2,287 | 1,971 |
Other | 1,526 | 407 |
Accrued expenses | $ 18,502 | $ 27,502 |
Other Commitments and Conting_2
Other Commitments and Contingencies - Additional Information (Details) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Indemnified Parties | ||
Loss Contingencies [Line Items] | ||
Liabilities accrued | $ 0 | $ 0 |
Equity-Based Compensation - Add
Equity-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Aug. 20, 2020 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Equity-based compensation expense | $ 9,385 | $ 7,873 | |
Research and Development Expense | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Equity-based compensation expense | 4,729 | 3,906 | |
General and Administrative | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Equity-based compensation expense | 4,656 | 3,967 | |
Stock Options | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Intrinsic value of stock options exercised | $ 5,500 | $ 6,200 | |
Weighted-average fair value of options granted | $ 18.67 | $ 22.96 | |
Unrecognized stock-based compensation expense | $ 82,500 | ||
Unrecognized compensation cost, recognition period | 2 years 4 months 24 days | ||
Equity-based compensation expense | $ 8,533 | $ 7,601 | |
Stock Options | Research and Development Expense | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Equity-based compensation expense | 4,184 | 3,689 | |
Stock Options | General and Administrative | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Equity-based compensation expense | $ 4,349 | $ 3,912 | |
Restricted Stock | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Unrecognized compensation cost, recognition period | 2 years 9 months 18 days | ||
Granted | 216,289 | 97,974 | |
Unrecognized stock-based compensation expense | $ 10,900 | ||
Equity-based compensation expense | 600 | ||
Restricted Stock | Research and Development Expense | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Equity-based compensation expense | 400 | ||
Restricted Stock | General and Administrative | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Equity-based compensation expense | $ 200 | $ 100 | |
2020 Plan | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Number of shares authorized for issuance under plan | 4,457,370 | ||
Maximum number of shares to be issued, percentage | 4% | ||
Shares remaining available for future grants | 4,003,824 | ||
2020 ESPP | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Number of shares authorized for issuance under plan | 445,653 | ||
Shares remaining available for future grants | 1,647,150 | ||
Share-based compensation, description | The 2020 ESPP initially reserves and authorizes the issuance of up to a total of 445,653 shares of common stock to participating employees. The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the lesser of (i) 438,898 shares of common stock, (ii) 1% of the Company’s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP | ||
2020 ESPP | Lesser of Potential Outcome 1 | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Maximum number of shares to be issued, percentage | 1% | ||
Number of additional shares authorized | 438,898 | ||
2018 Plan | Restricted Stock | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Granted | 216,289 |
Equity-Based Compensation - Sum
Equity-Based Compensation - Summary of Stock Option Activity (Details) - 2020 Plan - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] | ||
Outstanding at beginning of period | 6,757,289 | |
Granted | 1,930,540 | |
Exercised | (208,705) | |
Forfeited | (187,393) | |
Outstanding at end of period | 8,291,731 | 6,757,289 |
Exercisable at March 31, 2023 | 3,711,610 | |
Weighted Average Strike Price Per Option | ||
Outstanding at beginning of period | $ 27.60 | |
Granted | 31.25 | |
Exercised | 7.12 | |
Forfeited | 39.41 | |
Outstanding at end of period | 28.70 | $ 27.60 |
Exercisable at March 31, 2023 | $ 24.28 | |
Weighted Average Remaining Contractual Term (in years) | ||
Outstanding | 8 years 3 months 7 days | 8 years 3 days |
Exercisable at March 31, 2023 | 7 years 5 months 1 day | |
Aggregate Intrinsic Value | ||
Outstanding at beginning of period | $ 55,934 | |
Outstanding at end of period | 67,120 | $ 55,934 |
Exercisable at March 31, 2023 | $ 48,572 |
Equity-Based Compensation - S_2
Equity-Based Compensation - Summary of Equity-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Total equity-based compensation | $ 9,385 | $ 7,873 |
Research and Development | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Total equity-based compensation | 4,729 | 3,906 |
General and Administrative | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Total equity-based compensation | 4,656 | 3,967 |
Stock Options | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Total equity-based compensation | 8,533 | 7,601 |
Stock Options | Research and Development | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Total equity-based compensation | 4,184 | 3,689 |
Stock Options | General and Administrative | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Total equity-based compensation | $ 4,349 | $ 3,912 |
Equity-Based Compensation - S_3
Equity-Based Compensation - Summary of Weighted-Average Assumptions (Details) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | ||
Expected term (in years) | 5 years 9 months 25 days | 5 years 9 months 21 days |
Volatility | 62% | 62% |
Risk-free interest rate | 4.14% | 1.59% |
Dividend yield | 0% | 0% |
Equity-Based Compensation - S_4
Equity-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock - $ / shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Number of Units Outstanding | ||
Granted | 216,289 | 97,974 |
2018 Plan | ||
Number of Units Outstanding | ||
Unvested at beginning of period | 281,843 | |
Granted | 216,289 | |
Vested | (28,141) | |
Forfeited | (17,270) | |
Unvested at end of period | 452,721 | |
Grant Date Fair Value per Share | ||
Unvested at beginning of period | $ 23.64 | |
Granted | 30.84 | |
Vested | 38.53 | |
Forfeited | 25.84 | |
Unvested at end of period | $ 26.07 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | Jun. 30, 2022 | |
Income Tax Disclosure [Line Items] | |||
Income tax expense (benefit) | $ 0 | $ 0 | |
Net operating loss carryforwards period CARES Act | 5 years |
Net Loss per Share - Summary of
Net Loss per Share - Summary of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Earnings Per Share [Abstract] | ||
Net Loss | $ (40,928) | $ (36,684) |
Net loss | $ (40,928) | $ (36,684) |
Weighted average common shares outstanding, basic and diluted | 58,187,038 | 51,651,125 |
Weighted average common shares outstanding, basic and diluted | 58,187,038 | 51,651,125 |
Net loss per share, basic and diluted | $ (0.70) | $ (0.71) |
Net loss per share, basic and diluted | $ (0.70) | $ (0.71) |
Net Loss per Share - Schedule o
Net Loss per Share - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect (Details) - shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive stock | 8,744,452 | 7,241,028 |
Unvested Restricted Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive stock | 452,721 | 121,504 |
Options to Purchase Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive stock | 8,291,731 | 7,119,524 |